The key COVID-19 findings in immunology, distilled into a clear, readable brief. The evidence is here whenever you want to go deeper.
INSIDE THIS MONITOR
42cited sources
7available findings
Study findings updated
AI-assisted evidence summary. For general information. These findings are not individual medical advice or a clinician endorsement.
THE SHORT VERSION
What’s worth knowing.
The key findings, what they mean, and the context that matters.
THE HEADLINE TAKEAWAY60%
Immune dysfunction persisted months after infection in Long COVID
In the study, persistent immune dysfunction was detected in 60% of Long COVID patients.
The finding was detectable at 6-12 months post-infection in the study's Long COVID patients. The sample and definition of immune dysfunction are not available, so broader applicability cannot be assessed.
See the evidence
of Long COVID patients show persistent immune dysfunction
60%
Su Y, Yuan D, Chen DG, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185(5):881-895.e20.
Epstein-Barr virus reactivation was frequent in Long COVID
66-73%
Epstein-Barr virus reactivation was reported in 66-73% of people with Long COVID.
This is a descriptive proportion within a Long COVID population. The timing, sample details, and reactivation criteria are not available in this summary.
See the evidence
EBV Reactivation in Long COVID
66-73% 95% CI: 60-80%
Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of long COVID prevalence and its relationship to Epstein-Barr virus reactivation. Pathogens. 2021;10(6):763.
Functional autoantibodies were common in hospitalized COVID-19 patients
50-70%
Functional autoantibodies were reported in 50-70% of hospitalized patients with COVID-19.
The result concerns an antibody marker in hospitalized COVID-19, not later autoimmune disease. Study timing and design are not available in this summary.
See the evidence
Autoantibodies in Hospitalized Patients
50-70% 95% CI: 45-75%
Wang EY, Mao T, Klein J, et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021;595(7866):283-288.
Type I interferon deficiency was frequent in severe COVID-19
80-90%
Type I interferon deficiency was reported in 80-90% of patients with severe COVID-19.
This finding applies to severe COVID-19 and describes a specific immune pathway, not a treatment effect. Study timing and design are not available in this summary.
See the evidence
Type I IFN Deficiency in Severe COVID
80-90% 95% CI: 75-95%
Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369(6504):718-724.
Complement restored JN.1 neutralization in previously nonneutralizing sera
22 of 32
Compared with testing without added complement, adding complement restored detectable JN.1 neutralization in 22 of 32 previously nonneutralizing sera.
Serum neutralization titers against D614G, BA.1, XBB.1.5, and JN.1 also increased after complement was added. These are neutralization-assay results, not clinical outcomes.
See the evidence
JN.1 nonneutralizer sera that regained detectable neutralization in the presence of complement
22 of 32
Jungbauer-Groznica, Martin et al.. Complement augments antibody neutralization of SARS-CoV-2 variants.. Science translational medicine. 2026.
SARS-CoV-1 immune imprinting persisted in isolated antibodies
Approximately 60%
Approximately 60% of isolated monoclonal antibodies showed SARS-CoV-1 imprinting and targeted the conserved regions assessed after BF.7 breakthrough infection.
Twenty-year persistence was described in individuals sequentially infected with SARS-CoV-1 and SARS-CoV-2. The percentage concerns isolated antibodies after BF.7 breakthrough infection, not participants or clinical protection.
Study details & original results
Zhang, Qi et al.. Twenty-year persistence of SARS-CoV-1 immune imprinting shapes antibody responses to SARS-CoV-2 infection.. Immunity. 2026.
Isolated monoclonal antibodies that were SARS-1 imprinted and targeted conserved RBD regions in individuals sequentially infected with SARS-CoV-1 and SARS-CoV-2 following BF.7 breakthrough infection
Complement restored JN.1 neutralization in previously nonneutralizing sera
22 of 32
Compared with testing without added complement, adding complement restored detectable JN.1 neutralization in 22 of 32 previously nonneutralizing sera.
Serum neutralization titers against D614G, BA.1, XBB.1.5, and JN.1 also increased after complement was added. These are neutralization-assay results, not clinical outcomes.
Study details & original results
Jungbauer-Groznica, Martin et al.. Complement augments antibody neutralization of SARS-CoV-2 variants.. Science translational medicine. 2026.
JN.1 nonneutralizer sera that regained detectable neutralization in the presence of complement
22 of 32
Increase in serum neutralization titers against D614G, BA.1, XBB.1.5, and JN.1 after complement was added
Isolated monoclonal antibodies that were SARS-1 imprinted and targeted conserved RBD regions in individuals sequentially infected with SARS-CoV-1 and SARS-CoV-2 following BF.7 breakthrough infection
Tesch F, Ehm F, Vivirito A, et al. Incident autoimmune diseases in association with SARS-CoV-2 infection: a matched cohort study. Clin Rheumatol. 2023;42(10):2905-2914.
Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369(6504):718-724.
Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of long COVID prevalence and its relationship to Epstein-Barr virus reactivation. Pathogens. 2021;10(6):763.
Browse the 42 original sourcesThe complete bibliography behind this monitor.
[1]
Tesch F, Ehm F, Vivirito A, et al. Incident autoimmune diseases in association with SARS-CoV-2 infection: a matched cohort study. Clin Rheumatol. 2023;42(10):2905-2914.
Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369(6504):718-724.
Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of long COVID prevalence and its relationship to Epstein-Barr virus reactivation. Pathogens. 2021;10(6):763.
Zheng HY, Zhang M, Yang CX, et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol. 2020;17(5):541-543.
Diao B, Wang C, Tan Y, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. 2020;11:827.
Woodruff MC, Ramonell RP, Nguyen DC, et al. Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nat Immunol. 2020;21(12):1506-1516.
Son K, Jamil R, Chowdhury A, et al. Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long COVID. Eur Respir J. 2023;61(1):2200970.
Zollner A, Koch R, Jukic A, et al. Postacute COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel diseases. Gastroenterology. 2022;163(2):495-506.e8.
Patterson BK, Francisco EB, Yogendra R, et al. Persistence of SARS CoV-2 S1 protein in CD16+ monocytes in post-acute sequelae of COVID-19 (PASC) up to 15 months post-infection. Front Immunol. 2022;12:746021.
Del Valle DM, Kim-Schulze S, Huang HH, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26(10):1636-1643.
Peluso MJ, Lu S, Tang AF, et al. Markers of immune activation and inflammation in individuals with postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis. 2021;224(11):1839-1848.
Wilk AJ, Rustagi A, Zhao NQ, et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat Med. 2020;26(7):1070-1076.
Taquet M, Sillett R, Zhu L, et al. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1,284,437 patients. Lancet Psychiatry. 2022;9(10):815-827.
Sekine T, Perez-Potti A, Rivera-Ballesteros O, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell. 2020;183(1):158-168.e14.
This is an AI-assisted evidence summary, not a clinician endorsement. Read each original paper for its complete methods, population and limitations. Different studies can ask different questions and report different kinds of results.
Dates marked “added” describe when a finding entered this monitor, not when the study was published or clinically reviewed. Personal health and treatment decisions belong in a conversation with a qualified clinician.